Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis
Tóm tắt
To test the anticancer properties of a nonhydrolyzable ether-linked acetic acid analogue of vitamin E, 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxyacetic acid (α-TEA), and a derivative of camptothecin, 9-nitrocamptothecin (9-NC) singly and in combination against mouse mammary tumor cells (line 66 clone 4 stably transfected with green fluorescent protein; 66c1-4-GFP) cultured in vitro or transplanted subcutaneously into the inguinal region of female BALB/c mice to form established tumors. Following in vitro treatment of 66cl-4-GFP cells with α-TEA and suboptimal concentrations of 9-NC, singly or in combination, apoptosis was measured by morphological evaluation of nuclei stained with 4′,6-diamidino-2-phenylindole (DAPI), and DNA synthesis arrest was measured by tritiated thymidine uptake. For in vivo analyses α-TEA and 9-NC, both water-insoluble compounds, were formulated into liposomes using dilauroylphosphatidylcholine and administered by aerosol to deliver doses calculated to be 36 and 0.4 μg/mouse per day, respectively, (singly or each separately for combined treatments) 7 days per week. Treatment of 66cl-4-GFP cells in culture for 3 days with a combination of α-TEA (10 μg/ml; singly produces 38% apoptosis), and suboptimal concentrations of 9-NC (15.6, 31.3, 62.5, or 125 ng/ml; singly produce 2–7% apoptosis), produced 47%, 58%, 64%, and 69% apoptosis. Likewise, combinations of α-TEA + 9-NC inhibited DNA synthesis more than either agent administered singly. A significant reduction (P<0.001) in growth of subcutaneous transplanted tumors was observed with liposome-formulated and aerosolized delivery of α-TEA + 9-NC to BALB/c mice. The incidence of macroscopic lung metastasis was 83% in control vs 8% in α-TEA-, 9-NC-, or combination-treated mice. Fluorescence microscopic examination of lungs and axillary and brachial lymph nodes showed a statistically significant decrease in metastasis observed in α-TEA-, 9-NC-, and combination- vs control-treated animals. Analyses of primary tumor tissue for proliferation and apoptosis showed treatment groups to have lower Ki-67 and higher terminal deoxynucleotidyl transferase-mediated nick end labeling, respectively. Treatments showed no measurable effects on two angiogenesis parameters, namely intratumoral blood volume as assessed by hemoglobin content and intratumoral blood vessel density as assessed with CD31 staining. Combination treatments enhanced antiproliferative and proapoptotic activities in cell culture, and when formulated in liposomes and delivered via aerosolization to treat an aggressive and metastatic syngeneic murine mammary tumor, the combination treatment showed a significant reduction in tumor volume in comparison to either treatment alone. Mechanistically, it appears that neither enhanced apoptosis, reduced cell proliferation, nor reduced blood vessel density can fully account for the enhanced effects of the combination treatment.
Tài liệu tham khảo
Bandyopadhyay A, Lopez-Castillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun L-Z (2002) Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62:4690
Bernacki RJ, Pera P, Gambacorta P, Brun Y, Greco WR (2000) In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs. Ann N Y Acad Sci 922:293
Carpentier A, Groves S, Simmons-Menchaca M, Turley J, Zhao B, Sanders BG, Kline K (1993) RRR-alpha-tocopheryl succinate inhibits proliferation and enhances secretion of transforming growth factor-beta (TGF-beta) by human breast cancer cells. Nutr Cancer 19:225
Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, Peter ME, Wyche JH, Pantazis P (2001) Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP. Cancer Res 61:7148
Clarke R (1997) Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Res Treat 46:255
Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH (1978) Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38:3174
Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641
Gilbert BE, Seryshev A, Knight V, Brayton C (2002) 9-Nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol 14:185
Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, Vardeman DM (2002) Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (rubitecan). Int J Oncol 20:81
Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE (1999) Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44:177
Konstadoulakis MM, Antonakis PT, Tsibloulis AG, Stathopoulos GP, Manouras AP, Mylonaki DB, Golematis BX (2001) A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 48:417
Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V (1999) Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 44:187
Koshkina NV, Kleinerman ES, Waldrep C, Jai S-F, Worth LL, Gilbert BE, Knight V (2000) 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876
Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L-Z, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K (2003) Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2:437
Miller BE, Roi LD, Howard LM, Miller FR (1983) Quantitative selectivity of contact-mediated intercellular communication in a metastatic mouse mammary tumor line. Cancer Res 43:4102
Miller KD, Haney LG, Guiney P, Murry DJ, Hawes JW, Lenaz L, Aun S-L, Sledge GW (2000) A phase II pharmacokinetic and pharmacodynamic trial of 9-nitrocamptothecin (9-NC) in patients with metastatic breast cancer. Breast Cancer Res Treat 64:126
Pantazis P, Early JA, Mendoza JT, DeJesus AR, Giovanella BC (1994) Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 54:771
Shun M-C, Yu W, Atkinson J, Gapor A, Sanders BG, Kline K (2004) Pro-apoptotic mechanisms of action of a novel vitamin E analog (α-TEA) and a naturally occurring form of vitamin E (d=tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer (in press)
Ulukan H, Swaan W (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs 62:2039
Verschraegen CF, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Harris N, Steger M, Steltz V, Giovanella BC, Stehlin JS (1999) A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 10:375
Verschraegen CF, Gilbert BE, Huaringa AJ, Newman R, Harris N, Leyva FJ, Keus L, Campbell K, Nelson-Taylor T, Knight V (2002) Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann N Y Acad Sci 922:352
Wani MC, Ronman PE, Lindley JT, Wall ME (1980) Plant antitumor agents. Synthesis and biological activity of camptothecin analogues. J Med Chem 23:554